In a shocking discovery, scientists have found that tuberculosis strains in Russia carry mutations that not only make them resistant to antibiotics but also help them spread more effectively.
The latest study of TB cases in Russia indicates that rampant drug resistance may not be the only explanation for the TB rise in the region - biological factors also play a major role in it.
Researchers at Queen Mary University of London analysed 1,000 genomes from different TB isolates - the largest whole-genome study of a single bacterial species so far.
This enabled the team to identify previously unknown mutations linked to antibiotic resistance, as well as "compensatory mutations" that improve the ability of drug-resistant TB to spread.
Nearly half of the TB isolates were multi-drug resistant, which means that they were impervious to the two common first-line antibiotics that cure most TB infections.
Sixteen percent of these isolates also harboured mutations that made them impervious to "second-line" drugs.
These infections are more expensive to treat and patients who receive ineffective drugs are more likely to spread TB, said the research published in the journal Nature Genetics.
TB, which is caused by the bacterium Mycobacterium tuberculosis, exploded in Russia and other former Soviet nations in the early 1990s, after the collapse of the Soviet Union and its health system.
"It certainly adds an extra layer of worry, because one had assumed if you could solve 'programmatic' weaknesses, you would solve the problem of the drug-resistant TB," stressed Francis Drobniewski, a microbiologist at Queen Mary University.
"Although we know the general story of TB drug resistance in Russia, these new findings are still shocking," added Christopher Dye, an epidemiologist at the World Health Organisation (WHO) in Geneva.
According to Megan Murray, an epidemiologist at the Harvard School of Public Health in Boston, Massachusetts, the worst scenario is that the organisms are developing resistance, compensating for it, and evolving into something that's new and different, that's much less treatable.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
